Composition, preferably, in the form of capsules or chewable wafers in quantities suitable for relieving the symptoms of fibromyalgia comprise formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients are described.